Revvity Unveils Signals Xynthetica AI Models-as-a-Service to Accelerate Predictive Discovery

19 December 2025 | Friday | News

New Signals platform offering integrates in-silico design, predictive modeling, and experimental validation to operationalize AI-driven molecular and materials innovation

Revvity, Inc.  announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in‑silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and refine candidate molecules with increasing confidence.

Across life sciences and materials research, the application of artificial intelligence and machine learning is rapidly shifting discovery from trial-and-error experimentation toward predictive, data driven design. While powerful algorithms and models continue to emerge, their real‑world impact is limited without tight integration with high‑quality experimental data and the workflows scientists already use. The Signals Xynthetica offering is intended to address this gap by embedding models directly into the scientific context, connecting AI predictions with real wet-lab outcomes to drive continuous learning and improvement.

The Signals Xynthetica platform will support a wide range of in-silico design approaches, including de novo generation, property prediction, and multi-objective optimization. Delivered as an AI MaaS offering, it enables organizations to access, govern, and apply predictive models without building or maintaining a complex AI infrastructure. Models can be used consistently across projects, refreshed as new data emerges, and evaluated transparently alongside experimental results.

“AI has enormous potential to transform how molecules and materials are designed, but that potential is only realized when models are connected to real scientific workflows and data,” said Kevin Willoe, president of Revvity Signals Software. “The Signals Xynthetica platform is about operationalizing predictive science that brings in-silico design and experimental validation together in a continuous loop, accelerating discovery across industries.”

The Signals Xynthetica offering is expected to become a cornerstone of Revvity’s broader vision for AI-augmented discovery, enabling customers to harness predictive power at scale while maintaining strong governance, data stewardship, and scientific rigor. Pre-registration for customers is underway with early access programs available in 1H 2026.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close